CORE-IBD:为炎症性肠病随机对照试验制定核心结局指标集的国际多学科共识倡议
该国际多学科共识通过系统文献综述、患者参与调查和访谈生成候选结局域与测量工具,经迭代德尔菲流程(9点李克特量表匿名投票)和共识会议,由235例患者和53位专家参与,确定了克罗恩病和溃疡性结肠炎随机对照试验的核心结局域与核心结局测量指标。
要点
- 患者报告结局、生活质量、内镜、生物标志物和安全性为核心结局域,溃疡性结肠炎另加组织病理学。
- 克罗恩病共识采用2项患者报告结局、克罗恩病活动指数、简化内镜评分、C反应蛋白、粪便钙卫蛋白及症状缓解与内镜应答的共主要终点。
- 溃疡性结肠炎共识采用9点梅奥诊所评分、排便急迫感、Robarts组织病理学指数或Geboes评分、粪便钙卫蛋白及症状与内镜缓解的复合主要终点。
核心结论
- 该多学科协作涉及患者和临床专家,产生了首个可应用于克罗恩病和溃疡性结肠炎随机对照试验的核心结局指标集。
研究设计与样本
- 候选结局域和结局测量指标通过系统文献综述及患者参与调查和访谈生成。
- 采用迭代德尔菲流程建立共识:专家小组成员使用9点李克特量表匿名投票,轮次间纳入反馈以完善陈述。
- 召开共识会议批准结局域和核心结局测量指标。
- 利益相关者国际招募,包括胃肠病学家、结直肠外科医生、方法学家和临床试验研究者。
- 共235例患者和53位专家参与。
主要发现
- 患者报告结局、生活质量、内镜、生物标志物和安全性被视为核心结局域;组织病理学为溃疡性结肠炎的额外结局域。
- 克罗恩病共识采用2项患者报告结局(即腹痛和排便频率)、克罗恩病活动指数、简化克罗恩病内镜评分、C反应蛋白、粪便钙卫蛋白,以及症状缓解与内镜应答的共主要终点。
- 溃疡性结肠炎共识采用9点梅奥诊所评分、排便急迫感、Robarts组织病理学指数或Geboes评分、粪便钙卫蛋白,以及包含症状缓解和内镜缓解的复合主要终点。
- 安全性结局应使用监管活动医学词典报告。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: End points to determine the efficacy and safety of medical therapies for Crohn's disease (CD) and ulcerative colitis (UC) are evolving. Given the heterogeneity in current outcome measures, harmonizing end points in a core outcome set for randomized controlled trials is a priority for drug development in inflammatory bowel disease. METHODS: Candidate outcome domains and outcome measures were generated from systematic literature reviews and patient engagement surveys and interviews. An iterative Delphi process was conducted to establish consensus: panelists anonymously voted on items using a 9-point Likert scale, and feedback was incorporated between rounds to refine statements. Consensus meetings were held to ratify the outcome domains and core outcome measures. Stakeholders were recruited internationally, and included gastroenterologists, colorectal surgeons, methodologists, and clinical trialists. RESULTS: A total of 235 patients and 53 experts participated. Patient-reported outcomes, quality of life, endoscopy, biomarkers, and safety were considered core domains; histopathology was an additional domain for UC. In CD, there was consensus to use the 2-item patient-reported outcome (ie, abdominal pain and stool frequency), Crohn's Disease Activity Index, Simple Endoscopic Score for Crohn's Disease, C-reactive protein, fecal calprotectin, and co-primary end points of symptomatic remission and endoscopic response. In UC, there was consensus to use the 9-point Mayo Clinic Score, fecal urgency, Robarts Histopathology Index or Geboes Score, fecal calprotectin, and a composite primary end point including both symptomatic and endoscopic remission. Safety outcomes should be reported using the Medical Dictionary for Regulatory Activities. CONCLUSIONS: This multidisciplinary collaboration involving patients and clinical experts has produced the first core outcome set that can be applied to randomized controlled trials of CD and UC.
引用
- Ma C, Hanzel J, Panaccione R, et al. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022. PMID: 35788348. doi:10.1053/j.gastro.2022.06.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。